On the occasion of the main international event dedicated to the pharmaceutical industry, opening on October 8th in Milan, home of its HQ, Olon, the Italian Group recognized as a world leader in the development and production of APIs, confirms its participation (Hall 1, Booth B2). This year, Olon presents itself with an even stronger market position following two significant acquisitions that have expanded both its service offerings and production capacity. During the last quarter, Olon announced the acquisition of the French company GTP Bioways, an expert contract development and manufacturing organization (CDMO) specialized in process development and manufacturing of antibodies, proteins, bioconjugates, and nanodrugs, as well as HuvePharma Italia Srl and its site in Garessio, Cuneo, Italy. HuvePharma Italia Srl, with its plant in Garessio, is engaged in the development, industrialization, chemical synthesis, and manufacturing of active pharmaceutical ingredients, as well as advanced intermediates for the pharmaceutical industry.
With these latest acquisitions, Olon now operates a total of fourteen manufacturing plants across the globe, with an impressive reaction capacity of 3,250 cubic meters and a fermentation capacity of 5,000 cubic meters. In terms of geographical presence, the scale of its manufacturing network, and its installed production volume, Olon has emerged as one of the most significant industrial players both in Italy and across Europe.
Spanning three continents, Olon’s 14 state-of-the-art facilities offer highly diversified capabilities, including chemical synthesis, microbial fermentation, mammalian cell culture, bioconjugation, and Fill & Finish (F&F) processes. This extensive and versatile infrastructure reinforces Olon’s position as a global leader in pharmaceutical manufacturing, ensuring the ability to meet a wide range of client needs with precision and excellence.
GTP Bioways is a customer-centric and science-driven CDMO committed to offering uniquely customized process development and GMP manufacturing services for biologics, antibody-drug conjugates, and nanodrugs.
With cutting-edge facilities located in France, GTP Bioways can support biopharma companies from preclinical to commercial production of their innovative therapies. GTP Bioways’s services are seamlessly integrated with those of Olon.
This integration enables Olon to expand and diversify its technological offerings, supporting every stage of the lifecycle, from R&D and preclinical phases to commercial production through microbial and mammalian fermentation. Additionally, Olon will provide comprehensive services for the development and production of innovative ADC classes, offering a complete solution from mAbs to linkers, payloads, conjugation, and fill-and-finish.
Since its foundation, Olon Group has always pursued a strategy of growth, consolidation, and expansion in the global market, both organically and through acquisitions. These acquisitions, both domestic and international, have been successfully integrated into Olon’s vast and diversified global network, combining both chemical synthesis and microbial fermentation (biotechnology). Each acquisition has brought unique expertise to the Group, collectively enriching its technological capabilities and enhancing its competitiveness in the global market.
Olon Group stands as a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes, always embracing the highest international safety, quality, and environmental standards.
With 14 manufacturing sites and 9 R&D centers across the globe, and a dedicated team of 2,600 employees, including 350 highly qualified R&D experts, Olon remains a highly innovative, reliable, and trusted partner in the pharmaceutical industry.
